Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed/Refractory Neuroblastoma

NEW YORK--(BUSINESS WIRE)--Investigators from Baylor College of Medicine (BCM) in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify BTG1 as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. The study was published today in Nature Medicine.

As part of this collaboration, Immunai leveraged its advanced multi-omics platform to analyze clinical samples from an ongoing trial conducted at BCM. These studies led to the identification of BTG1 as a novel driver of NKT cell hyporesponsiveness that can be targeted to enhance CAR-NKT cell anti-tumor function. This discovery has the potential to improve the ability of NKT and T cell therapy products to target and eliminate malignant cells.

BCM conducted extensive in vitro and in vivo studies to validate the superior anti-tumor activity of CAR-NKT cells modified to target BTG1, demonstrating the potential of this approach for use as a cutting-edge therapy. Importantly, CAR-NKT cells genetically modified to target BTG1 were able to overcome exhaustion, a major obstacle for developing effective cell therapy products.

This breakthrough is significant as it opens the door to more effective and targeted immunotherapies to treat a range of malignancies and other diseases. By combining Immunai's expertise in multi-omics platforms with BCM’s research capabilities, the collaboration has paved the way for innovative treatment options that could improve patient outcomes worldwide.

“This project highlights Immunai’s platform capabilities in discovering and improving therapeutics, applicable to diverse types of cell therapies and other immune modulating therapies within oncology and inflammatory diseases,” said Noam Solomon, CEO of Immunai. “Immunai has been committed from the beginning to developing its cutting-edge platform to deliver actionable therapeutic insights that have the potential to transform patients’ lives, and our work with BCM is also a great reflection of our commitment to improving clinical outcomes with our partners.”

“Effectively harnessing knowledge from precious patient samples poses a paramount challenge in clinical research. The state-of-the-art single-cell RNA sequencing technology developed by Immunai allowed us to accurately measure gene expression changes in thousands of individual CAR-NKT cells before and after infusion into patients. The discoveries made during BCM and Immunai’s productive collaboration have already resulted in two Nature Medicine publications in less than three years and informed the development of more effective cancer immunotherapy,” said Dr. Leonid Metelitsa, Director, Center for Advanced Innate Cell Therapy at Texas Children's Hospital and Baylor College of Medicine.

The study was made possible through a long-standing collaboration between the two organizations structured around joint IP ownership, highlighting the power of combining industry-leading technology with top-tier academic research.

About Immunai

Founded in 2018, Immunai (New York HQ, offices in Tel-Aviv, Zurich and Prague) is an immune-profiling platform company for improving therapeutic discovery and development by measuring immunomics with single-cell resolution. Immunai holds the largest proprietary clinico-omics database AMICA™ for the human immune system from 10,000s of patients and spanning over 500 indications. Its core immune profiling platform leverages multi-modal profiling of immune cells of patients with single-cell resolution. The data is uploaded and harmonized in AMICA with engineering and ML infrastructure, and then mined for immune-driven therapeutic insights.Immunai is partnering with top hospitals, biopharma and biotechnology companies to co-develop novel therapeutics as well as accelerate clinical development programs with Immunai's platform.

About Baylor College of Medicine

Baylor College of Medicine (www.bcm.edu) in Houston is recognized as a health sciences university and is known for excellence in education, research and patient care. It is ranked 22nd among medical schools for research and 31st for primary care by U.S. News & World Report. Baylor is listed 20th among all U.S. medical schools for National Institutes of Health funding and No. 1 in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke’s Medical Center, part of St. Luke’s Health. Currently, Baylor has more than 3,000 trainees in medical, graduate, nurse anesthesia, physician assistant, orthotics and genetic counseling as well as residents and postdoctoral fellows.

Immunai Contacts:
Immunai
Chirag Sachar
chirag@immunai.com
www.immunai.com

Media:
Lauren Arnold
MacDougall Advisors
617-694-5387
Larnold@macdougall.bio

Baylor Contacts:
Media:
Molly Chiu
713-798-4710
Molly.chiu2@bcm.edu